Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
Clinical benefit in previously unresponsive tumors, including CRC, ovarian, and endometrial Confirmed responses in cold tumors as characterized by MSS No neuroendocrine toxicities or hypophysitis Registrational trials planned to commence in 2021 LEXINGTON …